Part 1: Continuing CDK4/6 inhibition and oral endocrine therapies
What are your options when HR+/HER2-negative metastatic breast cancer progresses on a CDK4/6 inhibitor? Prof. Wendy Chan (The University of Hong Kong) reviews the evidence on continuing CDK4/6 inhibition beyond progression. She also covers oral endocrine therapies for ESR1-mutated disease, including early switching guided by ctDNA monitoring, and the practical points of administration, adverse events, and monitoring.
- 0:00 Introduction and first-line CDK4/6 inhibitor therapy
- 1:18 Treatment strategies after CDK4/6 progression
- 1:50 Continuing CDK4/6 inhibition: MAINTAIN, postMONARCH, PALMIRA
- 3:56 Oral endocrine therapies in ESR1-mutated disease: EMERALD, EMBER-3, VERITAC-2
- 5:18 ctDNA-guided early switching: SERENA-6
- 6:01 Administration, adverse events, and monitoring
Part 2: Targeting the PI3K/AKT pathway
Up to half of patients with HR+/HER2-negative breast cancer have alterations in the PI3K/AKT/PTEN pathway. Prof. Chan walks through the pivotal trials for alpelisib, capivasertib, and inavolisib. She explains when to follow a negative liquid biopsy with tissue testing and compares the toxicity profiles you’ll need to manage in practice.
- 0:00 PI3K/AKT/PTEN pathway alterations
- 0:25 Alpelisib: SOLAR-1
- 1:15 Liquid vs tissue biopsy for PIK3CA testing
- 3:07 Capivasertib: CAPItello-291
- 6:03 Inavolisib: INAVO120
- 8:00 Comparing toxicities: rash and hyperglycemia
Part 3: Beyond endocrine therapy: PARP inhibitors and ADCs
When endocrine-based options run out, biomarkers guide what comes next. Prof. Chan covers PARP inhibitors for germline BRCA mutations and how the HER2 spectrum, including HER2-low and HER2-ultralow, opens the door to antibody-drug conjugates (ADCs). She closes with a practical approach to biomarker testing and a summary of post-CDK4/6 options.
- 0:00 Germline BRCA mutations and PARP inhibitors: OlympiAD, EMBRACA
- 1:43 The HER2 spectrum and trastuzumab deruxtecan: DESTINY-Breast04, DESTINY-Breast06
- 3:28 Sacituzumab govitecan: TROPiCS-02
- 4:41 Datopotamab deruxtecan: TROPION-Breast01
- 5:09 Biomarker testing: liquid and tissue biopsy, NGS
- 5:47 Summary and key takeaways